```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptau153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27  Source of Registration (SR) information in REGISTRY updated
                  and searchable
 NEWS  4  JAN 27  A new search aid, the Company Name Thesaurus, available in
                  CA/CAplus
 NEWS  5  FEB 05  German (DE) application and patent publication number format
                  changes
 NEWS  6  MAR 03  MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03  FRANCEPAT now available on STN
 NEWS  9  MAR 29  Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29  WPIFV now available on STN
 NEWS 11  MAR 29  New monthly current-awareness alert (SDI) frequency in RAPRA
 NEWS 12  APR 26  PROMT: New display field available
 NEWS 13  APR 26  IFIPAT/IFIUDB/IFICDB: New super search and display field
                  available
 NEWS 14  APR 26  LITALERT now available on STN
 NEWS 15  APR 27  NLDB: New search and display fields available
 NEWS 16  May 10  PROUSDDR now available on STN
 NEWS 17  May 19  PROUSDDR: One FREE connect hour, per account, in both May
                  and June 2004
 NEWS 18  May 12  EXTEND option available in structure searching
 NEWS 19  May 12  Polymer links for the POLYLINK command completed in REGISTRY
 NEWS 20  May 17  FRFULL now available on STN
 NEWS 21  May 27  STN User Update to be held June 7 and June 8 at the SLA 2004
                  Conference
 NEWS 22  May 27  New UPM (Update Code Maximum) field for more efficient patent
                  SDIs in CAplus
 NEWS 23  May 27  CAplus super roles and document types searchable in REGISTRY
 NEWS 24  May 27  Explore APOLLIT with free connect time in June 2004

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:16:02 ON 17 JUN 2004

=> file caplus uspatful europatful japio medline biosis embase
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 16:16:25 ON 17 JUN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:16:25 ON 17 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (c) 2004 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 16:16:25 ON 17 JUN 2004

FILE 'BIOSIS' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:16:25 ON 17 JUN 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

=> s implant? and device
L1       189288 IMPLANT? AND DEVICE

=> s l1 and (drug delivery)
   2 FILES SEARCHED...
L2        10581 L1 AND (DRUG DELIVERY)

=> s l2 and coat?
L3         6970 L2 AND COAT?

=> s l3 and barrier
L4         2673 L3 AND BARRIER

=> s l4 and biodegradable
L5         1182 L4 AND BIODEGRADABLE

=> s l5 and (rate control?)
L6          147 L5 AND (RATE CONTROL?)

=> s l6 and layer?
L7          131 L6 AND LAYER?

=> s l7 and substrate
L8           67 L7 AND SUBSTRATE

=> s l8 and (stent or graft or catheter or balloon)
L9           51 L8 AND (STENT OR GRAFT OR CATHETER OR BALLOON)

=> s l9 and uniform
L10           9 L9 AND UNIFORM
```

```
=> d l10 1-9 ibib abs

L10  ANSWER 1 OF 9  USPATFULL on STN
ACCESSION NUMBER:       2004:95568  USPATFULL
TITLE:                  Phosphorus-containing compounds and uses thereof
INVENTOR(S):            Metcalf, Chester A., III, Needham, MA, UNITED STATES
                        Rozamus, Leonard W., Bedford, MA, UNITED STATES
                        Wang, Yihan, Newton, MA, UNITED STATES
                        Berstein, David L., Waban, MA, UNITED STATES

                             NUMBER       KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2004073024      A1   20040415
APPLICATION INFO.:      US 2003-635054     A1   20030806 (10)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 2003-357152, filed
                        on 3 Feb 2003, PENDING

                               NUMBER        DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 2002-353252P    20020201 (60)
                        US 2002-426928P    20021115 (60)
                        US 2002-428383P    20021122 (60)
                        US 2002-433930P    20021217 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street,
                        Cambridge, MA, 02139-4234
NUMBER OF CLAIMS:       39
EXEMPLARY CLAIM:        1
LINE COUNT:             3658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       This invention concerns a new family of phosphorus-containing compounds
       containing a moiety JQA- in which:

       A is absent or is --O--, --S-- or --NR.sup.2--;

       Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--,
       --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic,
       heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to
       the cyclohexyl ring directly, through A or through VA, OVA, SVA or
       NR.sup.2VA;   ##STR1##

       K is O or S;

       each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a
       bond linking a R.sup.5 moiety to P;

       each occurrence of R and R is independently an aliphatic,
       heteroaliphatic, aryl, or heteroaryl moiety, or H; and

       each occurrence of R.sup.6 is independently --PK(YR.sup.5)(YR.sup.5),
       --SO.sub.2(YR.sup.5) or --C(O)(YR.sup.5); so long as any R or R.sup.5
       moiety linked directly to P is not H;

       wherein two R.sup.2, R.sup.5 and/or R.sup.6 moieties may be chemically
       linked to one another to form a ring;

       each occurrence of G is independently --O--, --S--, --NR.sup.2-- or
       (M).sub.x;

       each occurrence of M is independently a substituted or unsubstituted
       methylene moiety, and any M-M' moiety may be saturated or unsaturated;

       each occurrence of x is independently an integer from 1-6; and the other
```

```
          variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 2 OF 9  USPATFULL on STN
ACCESSION NUMBER:        2003:312692  USPATFULL
TITLE:                   Phosphorus-containing compounds and uses thereof
INVENTOR(S):             Berstein, David L., Waban, MA, UNITED STATES
                         Metcalf, Chester A., III, Needham, MA, UNITED STATES
                         Rozamus, Leonard W., Bedford, MA, UNITED STATES
                         Wang, Yihan, Newton, MA, UNITED STATES

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2003220297      A1   20031127
APPLICATION INFO.:       US 2003-357152     A1   20030203 (10)

                                NUMBER        DATE
                         ----------------- --------
PRIORITY INFORMATION:    US 2002-353252P    20020201 (60)
                         US 2002-426928P    20021115 (60)
                         US 2002-428383P    20021122 (60)
                         US 2002-433930P    20021217 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    David L. Berstein, ARIAD Gene Therapeutics, Inc., 26
                         Landsdowne Street, Cambridge, MA, 02139-4234
NUMBER OF CLAIMS:        39
EXEMPLARY CLAIM:         1
LINE COUNT:              3696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       This invention concerns a new family of phosphorus-containing compounds
         containing a moiety JQA--in which:

         A is absent or is --O--, --S-- or --NR.sup.2--;

         Q is absent or (if A is --O--, --S-- or --NR.sup.2--) Q may be --V--,
         --OV--, --SV--, or --NR.sup.2V--, where V is an aliphatic,
         heteroaliphatic, aryl, or heteroaryl moiety, such that J is linked to
         the cyclohexyl ring directly, through A or through VA, OVA, SVA or
         NR.sup.2VA;    ##STR1##

         K is O or S;

         each occurrence of Y is independently --O--, --S--, --NR.sup.2--, or a
         chemical bond linking a R.sup.5 moiety to P;

         and the other variables are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 3 OF 9  USPATFULL on STN
ACCESSION NUMBER:        2003:311966  USPATFULL
TITLE:                   Polymer coating for medical devices
INVENTOR(S):             Rypacek, Frantisek, Prague, CZECH REPUBLIC
                         Lapcikova, Monika, Prague, CZECH REPUBLIC
                         Machova, Ludka, Prague, CZECH REPUBLIC

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2003219562      A1   20031127
APPLICATION INFO.:       US 2003-366767     A1   20030214 (10)

                                NUMBER        DATE
```

PRIORITY INFORMATION: US 2002-357573P 20020215 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2870
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Coatings** are provided in which surfaces may be activated by covalently bonding a silane derivative to the metal surface, covalently bonding a lactone polymer to the silane derivative by in situ ring opening polymerization, and depositing at least one **layer** of a polyester on the bonded lactone. Biologically active agents may be deposited with the polyester **layers**. Such **coated** surfaces may be useful in medical devices, in particular stents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:121162 USPATFULL
TITLE: Apparatus and methods for variably controlled substance delivery from **implanted** prostheses
INVENTOR(S): Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S): AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003083646	A1	20030501	
APPLICATION INFO.:	US 2001-17500	A1	20011214	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 112
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 35 Drawing Page(s)
LINE COUNT: 2731

AB The present invention provides improved stents and other prostheses for delivering substances to vascular and other luminal and intracorporeal enviroments. In particular, the present invention provides luminal prostheses which allow for a programmed and controlled substance delivery protocols for a variety of purposes. The prostheses comprise a scaffold which is **implantable** within a body lumen and a substance reservoir present over at least a portion of the scaffold. Usually, a **rate-controlling** element will be formed over the substance-containing reservoir to provide for a number of different substance release characteristics.

L10 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:93678 USPATFULL
TITLE: Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
INVENTOR(S): Kharazmi, Arsalan, Hellerup, DENMARK
Christensen, Soren Brogger, Nivaa, DENMARK
Nielsen, Simon Feldbaek, Herlev, DENMARK

```
PATENT ASSIGNEE(S):      Statens Serum Institute, Copenhagen K, DENMARK
                         (non-U.S. corporation)

                             NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003065039      A1    20030403
APPLICATION INFO.:       US 2002-62208      A1    20020131  (10)
RELATED APPLN. INFO.:    Division of Ser. No. US 1999-462125, filed on 27 Dec
                         1999, PENDING A 371 of International Ser. No. WO
                         1998-DK283, filed on 26 Jun 1998, UNKNOWN

                               NUMBER        DATE
                         ----------------- --------
PRIORITY INFORMATION:    DK 1997-762        19970626
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,, INTELLECTUAL
                         PROPERTY PRACTICE GROUP, EDWARDS & ANGELL, LLP., P.O.
                         BOX 9169, BOSTON, MA, 02209
NUMBER OF CLAIMS:        335
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      37 Drawing Page(s)
LINE COUNT:              7715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones
         (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and
         1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical
         compositions for the treatment or prophylaxis of a number of serious
         diseases including i) conditions relating to harmful effects of
         inflammatory cytokines, ii) conditions involving infection by
         Helicobacter species, iii) conditions involving infection by viruses,
         iv) neoplastic disorders, and v) conditions caused by microorganisms or
         parasites. The invention also relates to novel chalcones and
         dihydrochalcones (especially alkoxy substituted variants) having
         advantageous substitution patterns with respect to their effect as drug
         substances, and to methods of preparing them, as well as to
         pharmaceutical compositions comprising the novel chalcones. Moreover,
         the present invention relates to a method for the isolation of
         Leishmania fumarate reductase, QSAR methodologies for selecting potent
         compounds for the above-mentioned purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 6 OF 9  USPATFULL on STN
ACCESSION NUMBER:        2003:4518  USPATFULL
TITLE:                   Drug delivery platform
INVENTOR(S):             Elkins, Christopher J., Redwood City, CA, UNITED STATES
                         Dake, Michael D., Stanford, CA, UNITED STATES
                         Waugh, Jacob M., Palo Alto, CA, UNITED STATES

                             NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003004564      A1    20030102
APPLICATION INFO.:       US 2002-101455     A1    20020311  (10)

                               NUMBER        DATE
                         ----------------- --------
PRIORITY INFORMATION:    US 2001-285383P    20010420 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD,
                         SUITE 200, MENLO PARK, CA, 94025
NUMBER OF CLAIMS:        50
EXEMPLARY CLAIM:         1
```

```
NUMBER OF DRAWINGS:     6 Drawing Page(s)
LINE COUNT:             1700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      A stent based drug delivery system. A
        biological agent of interest is entrapped within a matrix, which is
        loaded into channels on the surface of a stent. The matrix
        allows for release, usually sustained release, of the entrapped agent.
        The stent and matrix is sheathed with a covalently bound gel.
        In one embodiment of the invention, the stent is used to
        deliver therapeutic agents to a patient, providing the advantage of
        efficient delivery and sustained release of an agent at a localized
        site. In another embodiment of the invention, the drug
        delivery system is used for testing and comparison of candidate
        drugs in an in vivo setting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 7 OF 9  USPATFULL on STN
ACCESSION NUMBER:       2002:198316  USPATFULL
TITLE:                  Drug delivery devices comprising
                        biodegradable protein for the controlled
                        release of pharmacologically active agents and method
                        of making the drug delivery devices
INVENTOR(S):            Masters, David B., Hastings, MN, UNITED STATES
PATENT ASSIGNEE(S):     Gel-Del Technologies, Inc. (U.S. corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2002106410      A1    20020808
APPLICATION INFO.:      US 2001-14947      A1    20011211  (10)
RELATED APPLN. INFO.:   Continuation of Ser. No. US 1998-160421, filed on 25
                        Sep 1998, PATENTED

                               NUMBER        DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 1997-60048P     19970925 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   John F. Dolan, Fredrikson & Byron, P.A., 1100
                        International Centre, 900 Second Avenue South,
                        Minneapolis, MN, 55408-3397
NUMBER OF CLAIMS:       41
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     3 Drawing Page(s)
LINE COUNT:             1828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention relates to an improved method of making
        drug delivery devices for the controlled release of
        pharmacologically active agents and further, to drug
        delivery devices made by such method. More specifically, the
        present invention relates to a method of forming a film comprising one
        or more biodegradable polymeric materials, one or more
        pharmacologically active agents, and one or more biocompatible solvents.
        The film is then partially dried, rolled or otherwise shaped, and then
        compressed. In this manner, the amount of pharmacologically active
        agent(s) that can be incorporated into the drug
        delivery device is increased and the pharmacologically
        active agent(s) is/are substantially homogeneously distributed
        throughout the drug delivery device. As a
        result, the release characteristics of the pharmacologically active
        agent from the drug delivery device are
        enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L10  ANSWER 8 OF 9  USPATFULL on STN
ACCESSION NUMBER:       2002:48052  USPATFULL
TITLE:                  Protein matrix materials, devices and methods of making
                        and using thereof
INVENTOR(S):            Masters, David B., Hastings, MN, UNITED STATES

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2002028243      A1   20020307
APPLICATION INFO.:      US 2001-796170     A1   20010228  (9)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 1998-160421, filed
                        on 25 Sep 1998, ABANDONED

                               NUMBER        DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 2000-185420P    20000228 (60)
                        US 2000-222762P    20000803 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   John F. Dolan, Fredrikson & Byron, P.A., 1100
                        International Center, 900 Second Avenue South,
                        Minneapolis, MN, 55402
NUMBER OF CLAIMS:       89
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     32 Drawing Page(s)
LINE COUNT:             3903
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       The present invention relates to protein matrix materials and devices
         and the methods of making and using protein matrix materials and
         devices. More specifically the present invention relates to protein
         matrix materials and devices that may be utilized for various medical
         applications including, but not limited to, drug
         delivery devices for the controlled release of pharmacologically
         active agents, encapsulated or coated stent devices,
         vessels, tubular grafts, vascular grafts, wound healing devices
         including protein matrix suture material and meshes, skin/bone/tissue
         grafts, biocompatible electricity conducting matrices, clear protein
         matrices, protein matrix adhesion prevention barriers, cell scaffolding
         and other biocompatible protein matrix devices. Furthermore, the present
         invention relates to protein matrix materials and devices made by
         forming a film comprising one or more biodegradable protein
         materials, one or more biocompatible solvents and optionally one or more
         pharmacologically active agents. The film is then partially dried,
         rolled or otherwise shaped, and then compressed to form the desired
         protein matrix device.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10  ANSWER 9 OF 9  USPATFULL on STN
ACCESSION NUMBER:       2002:19086  USPATFULL
TITLE:                  Drug delivery devices comprising
                        biodegradable protein for the controlled
                        release of pharmacologically active agents and method
                        of making the drug delivery devices
INVENTOR(S):            Masters, David B., Hastings, MN, United States
PATENT ASSIGNEE(S):     Gel-Del Technologies, Inc., Saint Paul, MN, United
                        States (U.S. corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 6342250         B1   20020129
APPLICATION INFO.:      US 1998-160421          19980925  (9)
```

```
                                   NUMBER        DATE
                              ----------------- --------
PRIORITY INFORMATION:         US 1997-60048P     19970925 (60)
DOCUMENT TYPE:                Utility
FILE SEGMENT:                 GRANTED
PRIMARY EXAMINER:             Webman, Edward J.
LEGAL REPRESENTATIVE:         Fredrikson & Byron, PA
NUMBER OF CLAIMS:             33
EXEMPLARY CLAIM:              1
NUMBER OF DRAWINGS:           4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT:                   1740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention relates to an improved method of making
        drug delivery devices for the controlled release of
        pharmacologically active agents and further, to drug
        delivery devices made by such method. More specifically, the
        present invention relates to a method of forming a film comprising one
        or more biodegradable polymeric materials, one or more
        pharmacologically active agents, and one or more biocompatible solvents.
        The film is then partially dried, rolled or otherwise shaped, and then
        compressed. In this manner, the amount of pharmacologically active
        agent(s) that can be incorporated into the drug
        delivery device is increased and the pharmacologically
        active agent(s) is/are substantially homogeneously distributed
        throughout the drug delivery device. As a
        result, the release characteristics of the pharmacologically active
        agent from the drug delivery device are
        enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 16:16:02 ON 17 JUN 2004)

     FILE 'CAPLUS, USPATFULL, EUROPATFULL, JAPIO, MEDLINE, BIOSIS, EMBASE'
     ENTERED AT 16:16:25 ON 17 JUN 2004
L1       189288 S IMPLANT? AND DEVICE
L2        10581 S L1 AND (DRUG DELIVERY)
L3         6970 S L2 AND COAT?
L4         2673 S L3 AND BARRIER
L5         1182 S L4 AND BIODEGRADABLE
L6          147 S L5 AND (RATE CONTROL?)
L7          131 S L6 AND LAYER?
L8           67 S L7 AND SUBSTRATE
L9           51 S L8 AND (STENT OR GRAFT OR CATHETER OR BALLOON)
L10           9 S L9 AND UNIFORM

=> s l9 and discrete
L11         29 L9 AND DISCRETE

=> d L11 1-29 ibib abs

L11  ANSWER 1 OF 29  USPATFULL on STN
ACCESSION NUMBER:             2004:139369  USPATFULL
TITLE:                        Compounds and methods for modulating cell adhesion
INVENTOR(S):                  Blaschuk, Orest W., Westmount, CANADA
                              Gour, Barbara J., Kemptville, CANADA
                              Farookhi, Riaz, Montreal, CANADA
                              Ali, Anmar, San Diego, CA, UNITED STATES

                                 NUMBER        KIND    DATE
                              --------------- ------ --------
```

```
PATENT INFORMATION:      US 2004106545      A1    20040603
APPLICATION INFO.:       US 2003-632678     A1    20030801   (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2003-464071, filed
                         on 18 Jun 2003, PENDING Continuation of Ser. No. US
                         2000-544782, filed on 7 Apr 2000, GRANTED, Pat. No. US
                         6610821 Continuation-in-part of Ser. No. US
                         1999-458870, filed on 10 Dec 1999, GRANTED, Pat. No. US
                         6465427 Continuation-in-part of Ser. No. US
                         1999-357717, filed on 20 Jul 1999, GRANTED, Pat. No. US
                         6417325 Continuation-in-part of Ser. No. US
                         1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US
                         6346512 Continuation-in-part of Ser. No. US
                         1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US
                         6169071 Continuation-in-part of Ser. No. US
                         1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US
                         6031072 Continuation-in-part of Ser. No. US
                         2003-359546, filed on 4 Feb 2003, PENDING Continuation
                         of Ser. No. US 1999-248015, filed on 10 Feb 1999,
                         GRANTED, Pat. No. US 6562786 Continuation-in-part of
                         Ser. No. US 1997-996679, filed on 23 Dec 1997, GRANTED,
                         Pat. No. US 6169071 Continuation-in-part of Ser. No. US
                         1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US
                         6031072

                                NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 1996-21612P     19960712 (60)
                         US 1996-21612P     19960712 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                         AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:        54
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      61 Drawing Page(s)
LINE COUNT:              6219
AB       Cyclic peptides comprising a cadherin cell adhesion recognition sequence
         HAV, and compositions comprising such cyclic peptides, are provided.
         Methods for using such peptides for modulating cadherin-mediated cell
         adhesion in a variety of contexts are also provided.


L11  ANSWER 2 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2004:114177  USPATFULL
TITLE:                   Compositions and methods for cell dedifferentiation and
                         tissue regeneration
INVENTOR(S):             Keating, Mark T., Chestnut Hill, MA, UNITED STATES
                         Odelberg, Shannon J., Salt Lake City, UT, UNITED STATES
                         Poss, Kenneth D., Brookline, MA, UNITED STATES
PATENT ASSIGNEE(S):      University of Utah Research Foundation, Salt Lake City,
                         UT, UNITED STATES, 84112 (U.S. corporation)

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004087016      A1    20040506
APPLICATION INFO.:       US 2002-302812     A1    20021122   (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2003-275828, filed
                         on 4 Apr 2003, PENDING A 371 of International Ser. No.
                         WO 2001-US15582, filed on 14 May 2001, PENDING

                                NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-204080P    20000512 (60)
                         US 2000-204081P    20000512 (60)
```

```
                          US 2000-204082P    20000512 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA,
                          02110-2624
NUMBER OF CLAIMS:         63
EXEMPLARY CLAIM:          1
LINE COUNT:               10731
AB      The present invention provides methods and compositions to
        dedifferentiate a cell. The ability of the methods and compositions of
        the present invention to promote the dedifferentiation of differentiated
        cells, including terminally differentiated cells, can be used to promote
        regeneration of tissues and organs in vivo. The ability of the methods
        and compositions of the present invention to promote the
        dedifferentiation of differentiated cells, including terminally
        differentiated cells, can further be used to produce populations of stem
        or progenitor cells which can be used to promote regeneration of tissues
        and/or organs damaged by injury or disease. Accordingly, the present
        invention provides novel methods for the treatment of a wide range of
        injuries and diseases that affect many diverse cell types.


L11  ANSWER 3 OF 29  USPATFULL on STN
ACCESSION NUMBER:         2004:103636  USPATFULL
TITLE:                    Implantable drug delivery
                          patch
INVENTOR(S):              Theeuwes, Felix, Los Altos Hills, CA, United States
                          Nelson, Timothy S., Los Gatos, CA, United States
PATENT ASSIGNEE(S):       Durect Corporation, Cupertino, CA, United States (U.S.
                          corporation)

                               NUMBER       KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 6726920        B1    20040427
APPLICATION INFO.:        US 2000-668684          20000922  (9)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             GRANTED
PRIMARY EXAMINER:         Azpuru, Carlos A.
LEGAL REPRESENTATIVE:     Bell, Adam W.
NUMBER OF CLAIMS:         33
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       16 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:               1400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The present invention features devices and methods for delivery of drug
        to an internal organ surface by delivery of drug directly to the surface
        of the organ such that the drug traverses the organ surface and enters
        the organ tissue. The device is in the form of an
        implantable drug delivery patch comprising a
        first layer, which is generally substantially
        drug-impermeable. When the first layer is placed on an outer
        surface of an organ, a drug reservoir is defined by the first
        layer and the organ surface.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 4 OF 29  USPATFULL on STN
ACCESSION NUMBER:         2004:97377  USPATFULL
TITLE:                    Compounds and methods for modulating claudin-mediated
                          functions
INVENTOR(S):              Blaschuk, Orest W., Westmount, CANADA
                          Symonds, James Matthew, Ottawa, CANADA
                          Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):       Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.
                        corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6723700        B1    20040420
APPLICATION INFO.:      US 1999-282029          19990330   (9)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 1998-185908, filed
                        on 3 Nov 1998
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Chan, Christina
ASSISTANT EXAMINER:     Haddad, Maher
LEGAL REPRESENTATIVE:   Seed IP Law Group PLLC
NUMBER OF CLAIMS:       5
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:             5699
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Method for using modulating agents to enhance or inhibit
       claudin-mediated cell adhesion in a variety of in vivo and in vitro
       contexts are provided. Within certain embodiments, the modulating agents
       may be used to increase blood/brain barrier permeability. The
       modulating agents comprise at least one claudin cell adhesion
       recognition sequence or an antibody or fragment thereof that
       specifically binds the claudin cell adhesion recognition sequence.
       Modulating agents may additionally comprise one or more cell adhesion
       recognition sequence recognized by other adhesion molecules. Such
       modulating agents may, but need not, be linked to a targeting agent,
       drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 5 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:207837  USPATFULL
TITLE:                  Coadministration of transport protein with conjugated
                        cobalamin to deliver agents
INVENTOR(S):            Collins, Douglas A., Rochester, MN, UNITED STATES

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2003144198     A1    20030731
APPLICATION INFO.:      US 2002-262318    A1    20020930   (10)

                               NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 2001-326183P    20010928 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   Sherry M. Knowles, King & Spalding, 45th Floor, 191
                        Peachtree Street, N.E., Atlanta, GA, 30303
NUMBER OF CLAIMS:       36
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     1 Drawing Page(s)
LINE COUNT:             3375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Cobalamin transport proteins are administered in combination with
       cobalamin coupled to a diagnostic or pharmaceutically active agents to
       increase the extent of absorption of the diagnostic or pharmaceutically
       active agent. Cobalamin transport proteins include, but are not limited
       to intrinsic factor, transcobalamin I, transcobalamin II and
       transcobalamin III. The combination of the cobalamin or cobalamin
       derivative with the cobalamin transport protein provides enhanced
       cellular uptake.
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 6 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:159839  USPATFULL
TITLE:                  Compounds and methods for modulating adhesion molecule
                        function
INVENTOR(S):            Doherty, Patrick, Twickenham, UNITED KINGDOM
                        Blaschuk, Orest W., Westmount, CANADA
                        Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):     Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2003109454      A1   20030612
APPLICATION INFO.:      US 2002-193653     A1   20020710  (10)
RELATED APPLN. INFO.:   Continuation of Ser. No. US 1999-351048, filed on 9 Jul
                        1999, GRANTED, Pat. No. US 6472368 Continuation-in-part
                        of Ser. No. US 1998-113977, filed on 10 Jul 1998,
                        GRANTED, Pat. No. US 6277824
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                        AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:       62
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     12 Drawing Page(s)
LINE COUNT:             3931
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Modulating agents and methods for enhancing or inhibiting
       cadherin-mediated functions are provided. The modulating agents comprise
       at least an HAV binding motif, an analogue or peptidomimetic thereof, or
       an antibody or fragment thereof that specifically binds to such a motif.
       Modulating agents may additionally comprise one or more cell adhesion
       recognition sequences recognized by cadherins and/or other adhesion
       molecules. Such modulating agents may, but need not, be linked to a
       targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 7 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:121162  USPATFULL
TITLE:                  Apparatus and methods for variably controlled substance
                        delivery from implanted prostheses
INVENTOR(S):            Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
                        Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S):     AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2003083646      A1   20030501
APPLICATION INFO.:      US 2001-17500      A1   20011214  (10)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 2001-2595, filed on
                        1 Nov 2001, PENDING
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
                        CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:       112
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     35 Drawing Page(s)
LINE COUNT:             2731
AB      The present invention provides improved stents and other prostheses for
```

```
       delivering substances to vascular and other luminal and intracorporeal
       enviroments. In particular, the present invention provides luminal
       prostheses which allow for a programmed and controlled substance
       delivery protocols for a variety of purposes. The prostheses comprise a
       scaffold which is implantable within a body lumen and a
       substance reservoir present over at least a portion of the scaffold.
       Usually, a rate-controlling element will be formed
       over the substance-containing reservoir to provide for a number of
       different substance release characteristics.


L11  ANSWER 8 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:93775  USPATFULL
TITLE:                  Compounds and methods for modulating cell adhesion
INVENTOR(S):            Blaschuk, Orest W., Westmount, CANADA
                        Gour, Barbara J., Kemptville, CANADA
                        Farookhi, Riaz, Montreal, CANADA
                        Ali, Anmar, Ottawa, CANADA
PATENT ASSIGNEE(S):     McGill University, Montreal, CANADA (non-U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2003065136      A1   20030403
APPLICATION INFO.:      US 2002-105008     A1   20020322 (10)
RELATED APPLN. INFO.:   Division of Ser. No. US 1999-458870, filed on 10 Dec
                        1999, PENDING Continuation-in-part of Ser. No. US
                        1999-357717, filed on 20 Jul 1999, GRANTED, Pat. No. US
                        6417325 Continuation-in-part of Ser. No. US
                        1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US
                        6346512 Continuation-in-part of Ser. No. US
                        1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US
                        6169071 Continuation-in-part of Ser. No. US
                        1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US
                        6031072

                               NUMBER        DATE
                        ------------------ --------
PRIORITY INFORMATION:   US 1996-21612P     19960712 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                        AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:       50
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     56 Drawing Page(s)
LINE COUNT:             5166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Cyclic peptides comprising a cadherin cell adhesion recognition sequence
       HAV, and compositions comprising such cyclic peptides, are provided.
       Methods for using such peptides for modulating cadherin-mediated cell
       adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 9 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:93678  USPATFULL
TITLE:                  Biologically active 1,3-bis-aromatic-prop-2-en-1-ones,
                        1,3-bis-aromatic-propan-1-ones, and
                        1,3-bis-aromatic-prop-2-yn-1-ones
INVENTOR(S):            Kharazmi, Arsalan, Hellerup, DENMARK
                        Christensen, Soren Brogger, Nivaa, DENMARK
                        Nielsen, Simon Feldbaek, Herlev, DENMARK
PATENT ASSIGNEE(S):     Statens Serum Institute, Copenhagen K, DENMARK
```

```
                      (non-U.S. corporation)

                           NUMBER        KIND    DATE
                      ---------------- ------ --------
PATENT INFORMATION:   US 2003065039      A1   20030403
APPLICATION INFO.:    US 2002-62208      A1   20020131  (10)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-462125, filed on 27 Dec
                      1999, PENDING A 371 of International Ser. No. WO
                      1998-DK283, filed on 26 Jun 1998, UNKNOWN

                             NUMBER        DATE
                      ----------------- --------
PRIORITY INFORMATION: DK 1997-762        19970626
DOCUMENT TYPE:        Utility
FILE SEGMENT:         APPLICATION
LEGAL REPRESENTATIVE: DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,, INTELLECTUAL
                      PROPERTY PRACTICE GROUP, EDWARDS & ANGELL, LLP., P.O.
                      BOX 9169, BOSTON, MA, 02209
NUMBER OF CLAIMS:     335
EXEMPLARY CLAIM:      1
NUMBER OF DRAWINGS:   37 Drawing Page(s)
LINE COUNT:           7715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The invention relates to the use of 1,3-bis-aromatic-prop-2-en-1-ones
        (chalcones), 1,3-bis-aromatic-propan-1-ones (dihydrochalcones), and
        1,3-bis-aromatic-prop-2-yn-1-ones for the preparation of pharmaceutical
        compositions for the treatment or prophylaxis of a number of serious
        diseases including i) conditions relating to harmful effects of
        inflammatory cytokines, ii) conditions involving infection by
        Helicobacter species, iii) conditions involving infection by viruses,
        iv) neoplastic disorders, and v) conditions caused by microorganisms or
        parasites. The invention also relates to novel chalcones and
        dihydrochalcones (especially alkoxy substituted variants) having
        advantageous substitution patterns with respect to their effect as drug
        substances, and to methods of preparing them, as well as to
        pharmaceutical compositions comprising the novel chalcones. Moreover,
        the present invention relates to a method for the isolation of
        Leishmania fumarate reductase, QSAR methodologies for selecting potent
        compounds for the above-mentioned purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 10 OF 29  USPATFULL on STN
ACCESSION NUMBER:     2003:72405  USPATFULL
TITLE:                Delivery of therapeutic capable agents
INVENTOR(S):          Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
                      Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S):   Avantec Vascular Corporation, Sunnyvale, CA, 94089
                      (U.S. corporation)

                           NUMBER        KIND    DATE
                      ---------------- ------ --------
PATENT INFORMATION:   US 2003050692      A1   20030313
APPLICATION INFO.:    US 2002-206807     A1   20020725  (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-2595, filed on
                      1 Nov 2001, PENDING Continuation-in-part of Ser. No. US
                      2001-783253, filed on 13 Feb 2001, PENDING
                      Continuation-in-part of Ser. No. US 2001-782927, filed
                      on 13 Feb 2001, GRANTED, Pat. No. US 6471980
                      Continuation-in-part of Ser. No. US 2001-783254, filed
                      on 13 Feb 2001, PENDING Continuation-in-part of Ser.
                      No. US 2001-782804, filed on 13 Feb 2001, PENDING
                      Continuation-in-part of Ser. No. US 2001-17500, filed
                      on 14 Dec 2001, PENDING
```

```
                              NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2002-370703P    20020406 (60)
                         US 2002-355317P    20020207 (60)
                         US 2002-347473P    20020110 (60)
                         US 2001-308381P    20010726 (60)
                         US 2000-258024P    20001222 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
                         CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:        38
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      20 Drawing Page(s)
LINE COUNT:              2572
AB       Devices and methods for reducing, inhibiting, or treating restenosis and
         hyperplasia after intravascular intervention are provided. In
         particular, the present invention provides luminal prostheses which
         allow for controlled release of at least one therapeutic capable agent
         with increased efficacy to selected locations within a patient's
         vasculature to reduce restenosis. An intraluminal prosthesis may
         comprise an expandable structure and a source adjacent the expandable
         structure for releasing the therapeutic capable agent into a body lumen
         to reduce smooth muscle cell proliferation.


L11  ANSWER 11 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2003:38114  USPATFULL
TITLE:                   Compounds and methods for modulating junctional
                         adhesion molecule-mediated functions
INVENTOR(S):             Blaschuk, Orest W., Westmount, CANADA
                         Symonds, James Matthew, Ottawa, CANADA
                         Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):      Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.
                         corporation)

                            NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003027761      A1   20030206
APPLICATION INFO.:       US 2002-119537     A1   20020408  (10)
RELATED APPLN. INFO.:    Division of Ser. No. US 1999-324541, filed on 2 Jun
                         1999, GRANTED, Pat. No. US 6391855
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                         AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:        54
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      2 Drawing Page(s)
LINE COUNT:              2582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Methods for using modulating agents to enhance or inhibit junctional
         adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo
         and in vitro contexts are provided. The modulating agents comprise at
         least one JAM cell adhesion recognition sequence or an antibody or
         fragment thereof that specifically binds thee JAM cell adhesion
         recognition sequence. Modulating agents may additionally comprise one or
         more cell adhesion recognition sequences recognized by other adhesion
         molecules. Such modulating agents may, but need not, be linked to a
         targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L11  ANSWER 12 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2003:4518  USPATFULL
TITLE:                  Drug delivery platform
INVENTOR(S):            Elkins, Christopher J., Redwood City, CA, UNITED STATES
                        Dake, Michael D., Stanford, CA, UNITED STATES
                        Waugh, Jacob M., Palo Alto, CA, UNITED STATES

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2003004564      A1    20030102
APPLICATION INFO.:      US 2002-101455     A1    20020311  (10)

                               NUMBER         DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 2001-285383P    20010420 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD,
                        SUITE 200, MENLO PARK, CA, 94025
NUMBER OF CLAIMS:       50
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     6 Drawing Page(s)
LINE COUNT:             1700
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       A stent based drug delivery system. A
       biological agent of interest is entrapped within a matrix, which is
       loaded into channels on the surface of a stent. The matrix
       allows for release, usually sustained release, of the entrapped agent.
       The stent and matrix is sheathed with a covalently bound gel.
       In one embodiment of the invention, the stent is used to
       deliver therapeutic agents to a patient, providing the advantage of
       efficient delivery and sustained release of an agent at a localized
       site. In another embodiment of the invention, the drug
       delivery system is used for testing and comparison of candidate
       drugs in an in vivo setting.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 13 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2002:337929  USPATFULL
TITLE:                  COMPOUNDS AND METHODS FOR MODULATING CLAUDIN-MEDIATED
                        FUNCTIONS
INVENTOR(S):            BLASCHUK, OREST W., WESTMOUNT, CANADA
                        SYMONDS, JAMES MATTHEW, OTTAWA, CANADA
                        GOUR, BARBARA J., KEMPTVILLE, CANADA

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 2002193294      A1    20021219
APPLICATION INFO.:      US 1998-185908     A1    19981103  (9)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                        AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:       63
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     3 Drawing Page(s)
LINE COUNT:             4384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Methods for using modulating agents to enhance or inhibit
       claudin-mediated cell adhesion in a variety of in vivo and in vitro
       contexts are provided. Within certain embodiments, the modulating agents
       may be used to increase blood/brain barrier permeability. The
       modulating agents comprise at least one claudin cell adhesion
       recognition sequence or an antibody or fragment thereof that
       specifically binds the claudin cell adhesion recognition sequence.
       Modulating agents may additionally comprise one or more cell adhesion
       recognition sequences recognized by other adhesion molecules. Such
       modulating agents may, but need not, be linked to a targeting agent,
       drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 14 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2002:283259  USPATFULL
TITLE:                  Compounds and methods for modulating adhesion molecule
                        function
INVENTOR(S):            Doherty, Patrick, Twickenham, UNITED KINGDOM
                        Blaschuk, Orest W., Westmount, CANADA
                        Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):     Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6472368         B1   20021029
APPLICATION INFO.:      US 1999-351048          19990709  (9)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 1998-113977, filed
                        on 10 Jul 1998, now patented, Pat. No. US 6277824
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Chan, Christina Y.
ASSISTANT EXAMINER:     Haddad, Maher
LEGAL REPRESENTATIVE:   SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:       3
EXEMPLARY CLAIM:        2
NUMBER OF DRAWINGS:     13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:             3743
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Modulating agents and methods for enhancing or inhibiting
       cadherin-mediated functions are provided. The modulating agents comprise
       at least an HAV binding motif, an analogue or peptidomimetic thereof, or
       an antibody or fragment thereof that specifically binds to such a motif.
       Modulating agents may additionally comprise one or more cell adhesion
       recognition sequences recognized by cadherins and/or other adhesion
       molecules. Such modulating agents may, but need not, be linked to a
       targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 15 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2002:273397  USPATFULL
TITLE:                  Transcobalamin receptor binding conjugates useful for
                        treating abnormal cellular proliferation
INVENTOR(S):            Collins, Douglas A., Rochester, MN, UNITED STATES
                        Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2002151525      A1   20021017
APPLICATION INFO.:      US 2001-27593      A1   20011025  (10)

                               NUMBER        DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 2000-243082P    20001025 (60)
                        US 2000-243112P    20001025 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
```

```
LEGAL REPRESENTATIVE:    KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA,
                         GA, 30303-1763
NUMBER OF CLAIMS:        28
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      6 Drawing Page(s)
LINE COUNT:              4143
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       An agent, composition and method for the treatment, prophylaxis and/or
       diagnosis of proliferative disorders, which is highly and efficiently
       absorbed at the site of abnormal cellular proliferation is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 16 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2002:273347  USPATFULL
TITLE:                   Compounds and methods for modulating cell adhesion
INVENTOR(S):             Blaschuk, Orest W., Westmount, CANADA
                         Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):      McGill University, Montreal, CANADA, K1G 5Z3 (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002151475      A1   20021017
APPLICATION INFO.:       US 2001-6982       A1   20011204  (10)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 2000-507102, filed on 17
                         Feb 2000, GRANTED, Pat. No. US 6326352 Continuation of
                         Ser. No. US 1997-893534, filed on 11 Jul 1997, GRANTED,
                         Pat. No. US 6031072

                                NUMBER         DATE
                         ----------------- --------
PRIORITY INFORMATION:    US 1996-21612P     19960712 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH
                         AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS:        82
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      24 Drawing Page(s)
LINE COUNT:              2807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Cyclic peptides and compositions comprising such cyclic peptides are
       provided. The cyclic peptides comprise a cadherin cell adhesion
       recognition sequence HAV. Methods for using such peptides and
       compositions for modulating cadherin-mediated cell adhesion in a variety
       of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 17 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2002:268732  USPATFULL
TITLE:                   Compounds and methods for modulating cell adhesion
INVENTOR(S):             Blaschuk, Orest W., Westmount, CANADA
                         Gour, Barbara J., Kemptville, CANADA
                         Farookhi, Riaz, Montreal, CANADA
                         Ali, Anmar, Ottawa, CANADA
PATENT ASSIGNEE(S):      McGill University, Montreal, CANADA (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 6465427         B1   20021015
APPLICATION INFO.:       US 1999-458870          19991210  (9)
```

```
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1999-357717, filed
                         on 20 Jul 1999 Continuation-in-part of Ser. No. US
                         1999-248074, filed on 10 Feb 1999, now patented, Pat.
                         No. US 6346512 Continuation-in-part of Ser. No. US
                         1997-996679, filed on 23 Dec 1997, now patented, Pat.
                         No. US 6169071 Continuation-in-part of Ser. No. US
                         1997-893534, filed on 11 Jul 1997, now patented, Pat.
                         No. US 6031072

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 1996-21612P     19960712 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Davenport, Avis M.
LEGAL REPRESENTATIVE:    Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:        14
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      101 Drawing Figure(s); 56 Drawing Page(s)
LINE COUNT:              5017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Cyclic peptides comprising a cadherin cell adhesion recognition sequence
        HAV, and compositions comprising such cyclic peptides, are provided.
        Methods for using such peptides for modulating cadherin-mediated cell
        adhesion in a variety of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 18 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2002:158065  USPATFULL
TITLE:                   Delivery or therapeutic capable agents
INVENTOR(S):             Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
                         Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S):      AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S.
                         corporation)

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2002082679      A1   20020627
APPLICATION INFO.:       US 2001-2595       A1   20011101  (10)

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2000-258024P    20001222 (60)
                         US 2001-308381P    20010726 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
                         CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:        271
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      20 Drawing Page(s)
LINE COUNT:              3153
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      A device and a method using the same, for reducing restenosis
        and hyperplasia after intravascular intervention. In particular, the
        present invention provides luminal prostheses which allow for controlled
        release of at least one therapeutic capable agent with increased
        efficacy to selected locations within a patient's vasculature to reduce
        restenosis. An intraluminal prosthesis may comprise an expandable
        structure and a source adjacent the expandable structure for releasing
        the therapeutic capable agent into the body lumen to reduce smooth
        muscle cell proliferation.
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 19 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2002:116254  USPATFULL
TITLE:                  Compounds and methods for modulating junctional
                        adhesion molecule-mediated functions
INVENTOR(S):            Blaschuk, Orest W., Westmount, CANADA
                        Symonds, James Matthew, Ottawa, CANADA
                        Gour, Barbara J., Kemptville, CANADA
PATENT ASSIGNEE(S):     Adherex Technologies, Inc., Ottawa, CANADA (non-U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6391855        B1    20020521
APPLICATION INFO.:      US 1999-324541          19990602  (9)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Saunders, David
ASSISTANT EXAMINER:     DeCloux, Amy
LEGAL REPRESENTATIVE:   SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:       14
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:             2338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Methods for using modulating agents to enhance or inhibit junctional
        adhesion molecule (JAM)-mediated cell adhesion in a variety of in vivo
        and in vitro contexts are provided. The modulating agents comprise at
        least one JAM cell adhesion recognition sequence or an antibody or
        fragment thereof that specifically binds the JAM cell adhesion
        recognition sequence. Modulating agents may additionally comprise one or
        more cell adhesion recognition sequences recognized by other adhesion
        molecules. Such modulating agents may, but need not, be linked to a
        targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 20 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2002:92631  USPATFULL
TITLE:                  Cobalamin compounds useful as cardiovascular agents and
                        as imaging agents
INVENTOR(S):            Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

                             NUMBER        KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 2002049155     A1    20020425
APPLICATION INFO.:      US 2001-873142    A1    20010531  (9)

                               NUMBER         DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 2000-208140P    20000531 (60)
                        US 2001-267782P    20010209 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           APPLICATION
LEGAL REPRESENTATIVE:   KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA,
                        GA, 30303-1763
NUMBER OF CLAIMS:       50
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     2 Drawing Page(s)
LINE COUNT:             4521
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      The invention provides cobalamin derivatives linked to a cardiovascular
        agent, as well as pharmaceutical compositions comprising the compounds
```

```
       and methods for using the compounds in treatment or diagnosis of a
       cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 21 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2002:78737  USPATFULL
TITLE:                   Cobalamin compounds useful as antibiotic agents and as
                         imaging agents
INVENTOR(S):             Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
                         Collins, Douglas A., Rochester, MN, UNITED STATES

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2002042394      A1    20020411
APPLICATION INFO.:       US 2001-873164     A1    20010531  (9)

                                NUMBER        DATE
                         ----------------- --------
PRIORITY INFORMATION:    US 2000-208148P    20000531 (60)
                         US 2001-267543P    20010209 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA,
                         GA, 30303-1763
NUMBER OF CLAIMS:        50
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      2 Drawing Page(s)
LINE COUNT:              4896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides cobalamin derivatives linked to an antibiotic
       and/or an imaging agent, as well as pharmaceutical compositions
       comprising the compounds and methods for using the compounds in
       treatment or diagnosis of a microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 22 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2002:29367  USPATFULL
TITLE:                   Compounds and methods for modulating cell adhesion
INVENTOR(S):             Blaschuk, Orest W., Westmount, CANADA
                         Gour, Barbara J., Montreal, CANADA
PATENT ASSIGNEE(S):      McGill University, Montreal, CANADA (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 6346512         B1    20020212
APPLICATION INFO.:       US 1999-248074           19990210  (9)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 1997-996679, filed
                         on 23 Dec 1997 Continuation-in-part of Ser. No. US
                         1997-893534, filed on 11 Jul 1997, now patented, Pat.
                         No. US 6031072

                                NUMBER        DATE
                         ----------------- --------
PRIORITY INFORMATION:    US 1996-21612P     19960712 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Moezie, F. T.
LEGAL REPRESENTATIVE:    Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:        10
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      59 Drawing Figure(s); 38 Drawing Page(s)
```

```
LINE COUNT:              4110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Cyclic peptides and compositions comprising such cyclic peptides are
        provided. The cyclic peptides comprise a cadherin cell adhesion
        recognition sequence HAV. Methods for using such peptides and
        compositions for modulating cadherin-mediated cell adhesion in a variety
        of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 23 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2001:221030  USPATFULL
TITLE:                   Compounds and methods for modulating cell adhesion
INVENTOR(S):             Blaschuk, Orest W., Westmount, Canada
                         Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S):      McGill University, Montreal, Canada (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 6326352         B1   20011204
APPLICATION INFO.:       US 2000-507102          20000217  (9)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 1997-893534, filed on 11
                         Jul 1997, now patented, Pat. No. US 6031072

                                NUMBER        DATE
                         ---------------- --------
PRIORITY INFORMATION:    US 1996-21612P     19960712 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Davenport, Avis M.
LEGAL REPRESENTATIVE:    SEED Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:        22
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      45 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT:              2466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Cyclic peptides and compositions comprising such cyclic peptides are
        provided. The cyclic peptides comprise a cadherin cell adhesion
        recognition sequence HAV. Methods for using such peptides and
        compositions for modulating cadherin-mediated cell adhesion in a variety
        of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 24 OF 29  USPATFULL on STN
ACCESSION NUMBER:        2001:191243  USPATFULL
TITLE:                   Compounds and methods for modulating tissue
                         permeability
INVENTOR(S):             Blaschuk, Orest W., Westmount, Canada
                         Symonds, James Matthew, Ottawa, Canada
                         Gour, Barbara J., Kemptville, Canada
PATENT ASSIGNEE(S):      Adherex Technologies, Inc., Ottawa, Canada (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 6310177         B1   20011030
APPLICATION INFO.:       US 2000-510616          20000222  (9)
RELATED APPLN. INFO.:    Continuation of Ser. No. US 1997-1511, filed on 31 Dec
                         1997
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Davenport, Avis M.
```

```
LEGAL REPRESENTATIVE:   Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS:       31
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:             2343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Methods for using modulating agents to enhance or inhibit
        occludin-mediated cell adhesion in a variety of in vivo and in vitro
        contexts are provided. Within certain embodiments, the modulating agents
        may be used to increase vasopermeability. The modulating agents comprise
        at least one occludin cell adhesion recognition sequence or an antibody
        or fragment thereof that specifically binds the occludin cell adhesion
        recognition sequence. Modulating agents may additionally comprise one or
        more cell adhesion recognition sequences recognized by other adhesion
        molecules. Such modulating agents may, but need not, be linked to a
        targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 25 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2001:136627  USPATFULL
TITLE:                  Compounds and methods for modulating adhesion molecule
                        function
INVENTOR(S):            Doherty, Patrick, Twickenham, United Kingdom
                        Blaschuk, Orest W., Westmount, Canada
                        Gour, Barbara J., Montreal, Canada
PATENT ASSIGNEE(S):     Adherex Technologies, Ottawa, Canada (non-U.S.
                        corporation)

                             NUMBER        KIND    DATE
                        --------------- ------ --------
PATENT INFORMATION:     US 6277824         B1   20010821
APPLICATION INFO.:      US 1998-113977          19980710  (9)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           GRANTED
PRIMARY EXAMINER:       Chan, Christina Y.
ASSISTANT EXAMINER:     DiBrino, Marianne
LEGAL REPRESENTATIVE:   Seed IP Law Group PLLC
NUMBER OF CLAIMS:       11
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     12 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:             3160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Modulating agents and methods for enhancing or inhibiting
        cadherin-mediated functions are provided. The modulating agents comprise
        at least an HAV binding motif, an analogue or peptidomimetic thereof, or
        an antibody or fragment thereof that specifically binds to such a motif.
        Modulating agents may additionally comprise one or more cell adhesion
        recognition sequences recognized by cadherins and/or other adhesion
        molecules. Such modulating agents may, but need not, be linked to a
        targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 26 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2001:93630  USPATFULL
TITLE:                  Compounds and methods and modulating tissue
                        permeability
INVENTOR(S):            Blaschuk, Orest W., Westmount, Canada
                        Symonds, James Matthew, Ottawa, Canada
                        Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S):     Adherex Technologies, Inc., Ontario, Canada (non-U.S.
                        corporation)
```

```
                          NUMBER        KIND    DATE
                     --------------- ------ --------
PATENT INFORMATION:  US 6248864          B1   20010619
APPLICATION INFO.:   US 1997-1511             19971231  (9)
DOCUMENT TYPE:       Utility
FILE SEGMENT:        GRANTED
PRIMARY EXAMINER:    Davenport, Avis M.
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS:    17
EXEMPLARY CLAIM:     1
NUMBER OF DRAWINGS:  13 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:          2277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Methods for using modulating agents to enhance or inhibit
         occludin-mediated cell adhesion in a variety of in vivo and in vitro
         contexts are provided. Within certain embodiments, the modulating agents
         may be used to increase vasopermeability. The modulating agents comprise
         at least one occludin cell adhesion recognition sequence or an antibody
         or fragment thereof that specifically binds the occludin cell adhesion
         recognition sequence. Modulating agents may additionally comprise one or
         more cell adhesion recognition sequences recognized by other adhesion
         molecules. Such modulating agents may, but need not, be linked to a
         targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 27 OF 29  USPATFULL on STN
ACCESSION NUMBER:    2001:1758  USPATFULL
TITLE:               Compounds and methods for modulating cell adhesion
INVENTOR(S):         Blaschuk, Orest W., Westmount, Canada
                     Gour, Barbara J., Montreal, Canada
PATENT ASSIGNEE(S):  McGill University, Montreal, Canada (non-U.S.
                     corporation)

                          NUMBER        KIND    DATE
                     --------------- ------ --------
PATENT INFORMATION:  US 6169071          B1   20010102
APPLICATION INFO.:   US 1997-996679           19971223  (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-893534, filed
                     on 11 Jul 1997, now patented, Pat. No. US 6031072

                            NUMBER        DATE
                     ---------------- --------
PRIORITY INFORMATION: US 1996-21612P    19960712 (60)
DOCUMENT TYPE:       Utility
FILE SEGMENT:        Granted
PRIMARY EXAMINER:    Moezie, F. T.
LEGAL REPRESENTATIVE: Seed IP Law Group
NUMBER OF CLAIMS:    8
EXEMPLARY CLAIM:     1
NUMBER OF DRAWINGS:  55 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT:          3369
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       Cyclic peptides and compositions comprising such cyclic peptides are
         provided. The cyclic peptides comprise a cadherin cell adhesion
         recognition sequence HAV. Methods for using such peptides and
         compositions for modulating cadherin-mediated cell adhesion in a variety
         of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 28 OF 29  USPATFULL on STN
ACCESSION NUMBER:    2000:113775  USPATFULL
TITLE:               Compounds and methods for modulating tissue
```

```
                        permeability
INVENTOR(S):            Blaschuk, Orest W., Westmount, Canada
                        Symonds, James Matthew, Ottawa, Canada
                        Gour, Barbara J., Kemptville, Canada
PATENT ASSIGNEE(S):     Adherex Technologies Inc., Ottawa, Canada (non-U.S.
                        corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6110747              20000829
APPLICATION INFO.:      US 1998-222373          19981229  (9)
RELATED APPLN. INFO.:   Continuation-in-part of Ser. No. US 1997-1511, filed on
                        31 Dec 1997
DOCUMENT TYPE:          Utility
FILE SEGMENT:           Granted
PRIMARY EXAMINER:       Davenport, Avis M.
LEGAL REPRESENTATIVE:   Seed IP Law Group PLLC
NUMBER OF CLAIMS:       9
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     9 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT:             2887
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Methods for using modulating agents to enhance or inhibit
        occludin-mediated cell adhesion in a variety of in vivo and in vitro
        contexts are provided. Within certain embodiments, the modulating agents
        may be used to increase vasopermeability. The modulating agents comprise
        at least one occludin cell adhesion recognition sequence or an antibody
        or fragment thereof that specifically binds the occludin cell adhesion
        recognition sequence. Modulating agents may additionally comprise one or
        more cell adhesion recognition sequences recognized by other adhesion
        molecules. Such modulating agents may, but need not, be linked to a
        targeting agent, drug and/or support material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 29 OF 29  USPATFULL on STN
ACCESSION NUMBER:       2000:24746  USPATFULL
TITLE:                  Compounds and methods for modulating cell adhesion
INVENTOR(S):            Blaschuk, Orest W., Westmount, Canada
                        Gour, Barbara J., Beaconsfield, Canada
PATENT ASSIGNEE(S):     McGill University, Montreal, Canada (non-U.S.
                        corporation)

                             NUMBER       KIND    DATE
                        ---------------- ------ --------
PATENT INFORMATION:     US 6031072              20000229
APPLICATION INFO.:      US 1997-893534          19970711  (8)

                               NUMBER        DATE
                        ----------------- --------
PRIORITY INFORMATION:   US 1996-21612P     19960712 (60)
DOCUMENT TYPE:          Utility
FILE SEGMENT:           Granted
PRIMARY EXAMINER:       Davenport, Avis M.
LEGAL REPRESENTATIVE:   Seed and Berry LLP
NUMBER OF CLAIMS:       26
EXEMPLARY CLAIM:        1
NUMBER OF DRAWINGS:     17 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT:             2900
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Cyclic peptides and compositions comprising such cyclic peptides are
        provided. The cyclic peptides comprise a cadherin cell adhesion
        recognition sequence HAV. Methods for using such peptides and
        compositions for modulating cadherin-mediated cell adhesion in a variety
```

```
       of contexts are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> file uspatful
COST IN U.S. DOLLARS                                 SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                      128.54     128.75

FILE 'USPATFULL' ENTERED AT 16:32:08 ON 17 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 17 Jun 2004 (20040617/PD)
FILE LAST UPDATED: 17 Jun 2004 (20040617/ED)
HIGHEST GRANTED PATENT NUMBER: US6751803
HIGHEST APPLICATION PUBLICATION NUMBER: US2004117887
CA INDEXING IS CURRENT THROUGH 17 Jun 2004 (20040617/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 17 Jun 2004 (20040617/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2004
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2004

>>>  USPAT2 is now available.  USPATFULL contains full text of the      <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US          <<<
>>>  publications, starting in 2001, for the inventions covered in      <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original      <<<
>>>  published document but also a list of any subsequent               <<<
>>>  publications.  The publication number, patent kind code, and       <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL    <<<
>>>  records and may be searched in standard search fields, e.g., /PN,  <<<
>>>  /PK, etc.                                                          <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together         <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to           <<<
>>>  enter this cluster.                                                <<<
>>>                                                                     <<<
>>>  Use USPATALL when searching terms such as patent assignees,        <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                            <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s (drug delivery) and implant?
        140629 DRUG
        293102 DELIVERY
         26472 DRUG DELIVERY
                 (DRUG(W)DELIVERY)
        148676 IMPLANT?
L12      13094 (DRUG DELIVERY) AND IMPLANT?

=> s l12 and (sheath or barrier)
         69943 SHEATH
        202255 BARRIER
L13       5161 L12 AND (SHEATH OR BARRIER)

=> s l13 and caot?
           235 CAOT?
L14          2 L13 AND CAOT?

=> s l13 and coat?
        773478 COAT?
```

```
L15         4388 L13 AND COAT?

=> s l15 and substrate
          565560 SUBSTRATE
L16         2861 L15 AND SUBSTRATE

=> s l16 and partial?
         1317617 PARTIAL?
L17         2458 L16 AND PARTIAL?

=> s l17 and biodegradable
           32585 BIODEGRADABLE
L18         1412 L17 AND BIODEGRADABLE

=> s l18 and (rate control?)
         1150304 RATE
         2263764 CONTROL?
           23000 RATE CONTROL?
                   (RATE(W)CONTROL?)
L19           51 L18 AND (RATE CONTROL?)

=> s l19 an polymer?
MISSING OPERATOR L19 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> .
. IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s L19 and polymer?
          619461 POLYMER?
L20           51 L19 AND POLYMER?

=> s L20 and multilayer?
           73163 MULTILAYER?
L21            0 L20 AND MULTILAYER?

=> s L20 and (stent or catheter)
            9763 STENT
           46168 CATHETER
L22           21 L20 AND (STENT OR CATHETER)

=> d l22 1-21

L22  ANSWER 1 OF 21  USPATFULL on STN
AN      2004:139369  USPATFULL
TI      Compounds and methods for modulating cell adhesion
IN      Blaschuk, Orest W., Westmount, CANADA
        Gour, Barbara J., Kemptville, CANADA
        Farookhi, Riaz, Montreal, CANADA
        Ali, Anmar, San Diego, CA, UNITED STATES
PI      US 2004106545       A1   20040603
AI      US 2003-632678      A1   20030801 (10)
RLI     Continuation-in-part of Ser. No. US 2003-464071, filed on 18 Jun 2003,
        PENDING Continuation of Ser. No. US 2000-544782, filed on 7 Apr 2000,
        GRANTED, Pat. No. US 6610821 Continuation-in-part of Ser. No. US
        1999-458870, filed on 10 Dec 1999, GRANTED, Pat. No. US 6465427
        Continuation-in-part of Ser. No. US 1999-357717, filed on 20 Jul 1999,
        GRANTED, Pat. No. US 6417325 Continuation-in-part of Ser. No. US
        1999-248074, filed on 10 Feb 1999, GRANTED, Pat. No. US 6346512
        Continuation-in-part of Ser. No. US 1997-996679, filed on 23 Dec 1997,
        GRANTED, Pat. No. US 6169071 Continuation-in-part of Ser. No. US
        1997-893534, filed on 11 Jul 1997, GRANTED, Pat. No. US 6031072
        Continuation-in-part of Ser. No. US 2003-359546, filed on 4 Feb 2003,
        PENDING Continuation of Ser. No. US 1999-248015, filed on 10 Feb 1999,
        GRANTED, Pat. No. US 6562786 Continuation-in-part of Ser. No. US
        1997-996679, filed on 23 Dec 1997, GRANTED, Pat. No. US 6169071
        Continuation-in-part of Ser. No. US 1997-893534, filed on 11 Jul 1997,
        GRANTED, Pat. No. US 6031072
PRAI    US 1996-21612P      19960712 (60)
        US 1996-21612P      19960712 (60)
DT      Utility
FS      APPLICATION
LN.CNT 6219
INCL    INCLM: 514/009.000
        INCLS: 530/317.000
NCL     NCLM:  514/009.000
        NCLS:  530/317.000
IC      [7]
        ICM: A61K038-12
        ICS: C07K005-12; C07K007-64

L22  ANSWER 2 OF 21  USPATFULL on STN
AN      2004:114177  USPATFULL
TI      Compositions and methods for cell dedifferentiation and tissue
        regeneration
IN      Keating, Mark T., Chestnut Hill, MA, UNITED STATES
        Odelberg, Shannon J., Salt Lake City, UT, UNITED STATES
        Poss, Kenneth D., Brookline, MA, UNITED STATES
PA      University of Utah Research Foundation, Salt Lake City, UT, UNITED
        STATES, 84112 (U.S. corporation)
PI      US 2004087016       A1   20040506
AI      US 2002-302812      A1   20021122 (10)
RLI     Continuation-in-part of Ser. No. US 2003-275828, filed on 4 Apr 2003,
        PENDING A 371 of International Ser. No. WO 2001-US15582, filed on 14 May
        2001, PENDING
PRAI    US 2000-204080P     20000512 (60)
        US 2000-204081P     20000512 (60)
        US 2000-204082P     20000512 (60)
DT      Utility
FS      APPLICATION
LN.CNT 10731
INCL    INCLM: 435/366.000
        INCLS: 424/093.700
NCL     NCLM:  435/366.000
        NCLS:  424/093.700
IC      [7]
        ICM: C12N005-08
        ICS: A61K045-00

L22  ANSWER 3 OF 21  USPATFULL on STN
AN      2004:108237  USPATFULL
TI      N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment
        of cell proliferative disorders
IN      Ho, Chih Yung, Lansdale, PA, UNITED STATES
        Brunmark, Bengt Anders, LaJolla, CA, UNITED STATES
        Emanuel, Stuart, Doylestown, PA, UNITED STATES
        Galemmo, Robert A., JR., Collegeville, PA, UNITED STATES
        Johnson, Dana L., Upper Black Eddy, PA, UNITED STATES
        Ludovici, Donald W., Quakertown, PA, UNITED STATES
        Maharoof, Umar, North Wales, PA, UNITED STATES
        Mei, Jay M., North Wales, PA, UNITED STATES
        Sechler, Jan L., Doylestown, PA, UNITED STATES
        Strobel, Eric D., Hatboro, PA, UNITED STATES
        Tuman, Robert W., Chalfont, PA, UNITED STATES
```

```
       Yen, Hwa Kwo, Malvern, PA, UNITED STATES
PI     US 2004082639      A1   20040429
AI     US 2003-438152     A1   20030514 (10)
PRAI   US 2002-380735P     20020515 (60)
DT     Utility
FS     APPLICATION
LN.CNT 13168
INCL   INCLM: 514/405.000
       INCLS: 548/359.100; 548/360.100
NCL    NCLM:  514/405.000
       NCLS:  548/359.100; 548/360.100
IC     [7]
       ICM: A61K031-415
       ICS: C07D231-56; C07D231-54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 4 OF 21  USPATFULL on STN
AN     2004:103636  USPATFULL
TI     Implantable drug delivery patch
IN     Theeuwes, Felix, Los Altos Hills, CA, United States
       Nelson, Timothy S., Los Gatos, CA, United States
PA     Durect Corporation, Cupertino, CA, United States (U.S. corporation)
PI     US 6726920         B1   20040427
AI     US 2000-668684          20000922 (9)
DT     Utility
FS     GRANTED
LN.CNT 1400
INCL   INCLM: 424/423.000
       INCLS: 424/422.000; 424/424.000; 424/425.000; 424/426.000; 424/447.000;
              424/448.000; 424/449.000; 604/019.000
NCL    NCLM:  424/423.000
       NCLS:  424/422.000; 424/424.000; 424/425.000; 424/426.000; 424/447.000;
              424/448.000; 424/449.000; 604/019.000
IC     [7]
       ICM: A61F002-02
       ICS: A61F013-02; A61L015-16; A61K009-70; A61N001-30
EXF    424/422; 424/423; 424/424; 424/425; 424/426; 424/447; 424/448; 424/449;
       604/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 5 OF 21  USPATFULL on STN
AN     2004:95568  USPATFULL
TI     Phosphorus-containing compounds and uses thereof
IN     Metcalf, Chester A., III, Needham, MA, UNITED STATES
       Rozamus, Leonard W., Bedford, MA, UNITED STATES
       Wang, Yihan, Newton, MA, UNITED STATES
       Berstein, David L., Waban, MA, UNITED STATES
PI     US 2004073024      A1   20040415
AI     US 2003-635054     A1   20030806 (10)
RLI    Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb 2003,
       PENDING
PRAI   US 2002-353252P     20020201 (60)
       US 2002-426928P     20021115 (60)
       US 2002-428383P     20021122 (60)
       US 2002-433930P     20021217 (60)
DT     Utility
FS     APPLICATION
LN.CNT 3658
INCL   INCLM: 540/456.000
NCL    NCLM:  540/456.000
IC     [7]
       ICM: C07D498-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L22  ANSWER 6 OF 21  USPATFULL on STN
AN      2004:30716  USPATFULL
TI      Polymer-based, sustained release drug
        delivery system
IN      Ashton, Paul, Boston, MA, UNITED STATES
        Chen, Jianbing, Belmont, MA, UNITED STATES
        Guo, Hong, Belmont, MA, UNITED STATES
PA      Control Delivery Systems, Inc., Watertown, MA, UNITED STATES (U.S.
        corporation)
PI      US 2004022853       A1   20040205
AI      US 2003-449855      A1   20030530 (10)
RLI     Continuation-in-part of Ser. No. US 2002-134033, filed on 26 Apr 2002,
        PENDING Continuation-in-part of Ser. No. WO 2002-US13385, filed on 26
        Apr 2002, PENDING
PRAI    US 2001-286343P      20010426 (60)
        US 2001-322428P      20010917 (60)
        US 2002-372761P      20020415 (60)
DT      Utility
FS      APPLICATION
LN.CNT 1789
INCL    INCLM: 424/468.000
NCL     NCLM:  424/468.000
IC      [7]
        ICM: A61K009-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 7 OF 21  USPATFULL on STN
AN      2003:312692  USPATFULL
TI      Phosphorus-containing compounds and uses thereof
IN      Berstein, David L., Waban, MA, UNITED STATES
        Metcalf, Chester A., III, Needham, MA, UNITED STATES
        Rozamus, Leonard W., Bedford, MA, UNITED STATES
        Wang, Yihan, Newton, MA, UNITED STATES
PI      US 2003220297       A1   20031127
AI      US 2003-357152      A1   20030203 (10)
PRAI    US 2002-353252P      20020201 (60)
        US 2002-426928P      20021115 (60)
        US 2002-428383P      20021122 (60)
        US 2002-433930P      20021217 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3696
INCL    INCLM: 514/080.000
        INCLS: 540/456.000
NCL     NCLM:  514/080.000
        NCLS:  540/456.000
IC      [7]
        ICM: A61K031-675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 8 OF 21  USPATFULL on STN
AN      2003:207837  USPATFULL
TI      Coadministration of transport protein with conjugated cobalamin to
        deliver agents
IN      Collins, Douglas A., Rochester, MN, UNITED STATES
PI      US 2003144198       A1   20030731
AI      US 2002-262318      A1   20020930 (10)
PRAI    US 2001-326183P      20010928 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3375
INCL    INCLM: 514/012.000
        INCLS: 514/052.000; 530/350.000
NCL     NCLM:  514/012.000
```

```
        NCLS:  514/052.000; 530/350.000
IC      [7]
        ICM: A61K038-17
        ICS: A61K031-714; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 9 OF 21  USPATFULL on STN
AN      2003:121162  USPATFULL
TI      Apparatus and methods for variably controlled substance delivery from
        implanted prostheses
IN      Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
        Yan, John, Los Gatos, CA, UNITED STATES
PA      AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)
PI      US 2003083646      A1   20030501
AI      US 2001-17500      A1   20011214 (10)
RLI     Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001,
        PENDING
DT      Utility
FS      APPLICATION
LN.CNT 2731
INCL    INCLM: 604/891.100
        INCLS: 623/001.150; 623/001.420
NCL     NCLM:  604/891.100
        NCLS:  623/001.150; 623/001.420
IC      [7]
        ICM: A61F002-06

L22  ANSWER 10 OF 21  USPATFULL on STN
AN      2003:101978  USPATFULL
TI      Drug delivery catheters that attach to tissue and
        methods for their use
IN      Altman, Peter A., South San Francisco, CA, United States
        Hakem, Brian, South San Francisco, CA, United States
PA      BioCardia, Inc., San Francisco, CA, United States (U.S. corporation)
PI      US 6547787         B1   20030415
AI      US 1999-418206          19991013 (9)
RLI     Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997
DT      Utility
FS      GRANTED
LN.CNT 2046
INCL    INCLM: 606/041.000
        INCLS: 607/003.000; 607/120.000
NCL     NCLM:  606/041.000
        NCLS:  607/003.000; 607/120.000
IC      [7]
        ICM: A61N001-05
EXF     606/41; 606/47; 606/85; 606/48; 606/44; 600/374; 600/508; 600/424;
        607/3; 607/120-122; 607/126-128; 607/60-61; 607/32-33

L22  ANSWER 11 OF 21  USPATFULL on STN
AN      2003:72405  USPATFULL
TI      Delivery of therapeutic capable agents
IN      Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
        Yan, John, Los Gatos, CA, UNITED STATES
PA      Avantec Vascular Corporation, Sunnyvale, CA, 94089 (U.S. corporation)
PI      US 2003050692      A1   20030313
AI      US 2002-206807     A1   20020725 (10)
RLI     Continuation-in-part of Ser. No. US 2001-2595, filed on 1 Nov 2001,
        PENDING Continuation-in-part of Ser. No. US 2001-783253, filed on 13 Feb
        2001, PENDING Continuation-in-part of Ser. No. US 2001-782927, filed on
        13 Feb 2001, GRANTED, Pat. No. US 6471980 Continuation-in-part of Ser.
        No. US 2001-783254, filed on 13 Feb 2001, PENDING Continuation-in-part
        of Ser. No. US 2001-782804, filed on 13 Feb 2001, PENDING
        Continuation-in-part of Ser. No. US 2001-17500, filed on 14 Dec 2001,
       PENDING
PRAI   US 2002-370703P     20020406 (60)
       US 2002-355317P     20020207 (60)
       US 2002-347473P     20020110 (60)
       US 2001-308381P     20010726 (60)
       US 2000-258024P     20001222 (60)
DT     Utility
FS     APPLICATION
LN.CNT 2572
INCL   INCLM: 623/001.420
       INCLS: 623/001.430
NCL    NCLM:  623/001.420
       NCLS:  623/001.430
IC     [7]
       ICM: A61F002-06

L22  ANSWER 12 OF 21  USPATFULL on STN
AN     2003:4518  USPATFULL
TI     Drug delivery platform
IN     Elkins, Christopher J., Redwood City, CA, UNITED STATES
       Dake, Michael D., Stanford, CA, UNITED STATES
       Waugh, Jacob M., Palo Alto, CA, UNITED STATES
PI     US 2003004564      A1   20030102
AI     US 2002-101455     A1   20020311 (10)
PRAI   US 2001-285383P     20010420 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1700
INCL   INCLM: 623/001.150
NCL    NCLM:  623/001.150
IC     [7]
       ICM: A61F002-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 13 OF 21  USPATFULL on STN
AN     2002:315281  USPATFULL
TI     Drug delivery catheters that attach to tissue and
       methods for their use
IN     Altman, Peter A., South San Francisco, CA, UNITED STATES
       Altman, John D., South San Francisco, CA, UNITED STATES
       Stertzer, Simon, South San Francisco, CA, UNITED STATES
PI     US 2002177772      A1   20021128
AI     US 2002-190429     A1   20020705 (10)
RLI    Continuation of Ser. No. US 1999-418205, filed on 13 Oct 1999, GRANTED,
       Pat. No. US 6416510 Continuation-in-part of Ser. No. US 1997-816850,
       filed on 13 Mar 1997, GRANTED, Pat. No. US 6086582
DT     Utility
FS     APPLICATION
LN.CNT 2055
INCL   INCLM: 600/431.000
       INCLS: 607/120.000
NCL    NCLM:  600/431.000
       NCLS:  607/120.000
IC     [7]
       ICM: A61N001-00

L22  ANSWER 14 OF 21  USPATFULL on STN
AN     2002:273397  USPATFULL
TI     Transcobalamin receptor binding conjugates useful for treating abnormal
       cellular proliferation
IN     Collins, Douglas A., Rochester, MN, UNITED STATES
       Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI     US 2002151525      A1   20021017
AI     US 2001-27593      A1   20011025 (10)
```

```
PRAI    US 2000-243082P     20001025 (60)
        US 2000-243112P     20001025 (60)
DT      Utility
FS      APPLICATION
LN.CNT  4143
INCL    INCLM: 514/080.000
        INCLS: 540/145.000
NCL     NCLM:  514/080.000
        NCLS:  540/145.000
IC      [7]
        ICM: A61K031-675
        ICS: C07F015-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 15 OF 21  USPATFULL on STN
AN      2002:198316  USPATFULL
TI      Drug delivery devices comprising
        biodegradable protein for the controlled release of
        pharmacologically active agents and method of making the drug
        delivery devices
IN      Masters, David B., Hastings, MN, UNITED STATES
PA      Gel-Del Technologies, Inc. (U.S. corporation)
PI      US 2002106410       A1   20020808
AI      US 2001-14947       A1   20011211 (10)
RLI     Continuation of Ser. No. US 1998-160421, filed on 25 Sep 1998, PATENTED
PRAI    US 1997-60048P      19970925 (60)
DT      Utility
FS      APPLICATION
LN.CNT  1828
INCL    INCLM: 424/484.000
        INCLS: 514/002.000
NCL     NCLM:  424/484.000
        NCLS:  514/002.000
IC      [7]
        ICM: A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 16 OF 21  USPATFULL on STN
AN      2002:167670  USPATFULL
TI      Drug delivery catheters that attach to tissue and
        methods for their use
IN      Altman, Peter A., South San Francisco, CA, United States
        Altman, John D., South San Francisco, CA, United States
        Stertzer, Simon, South San Francisco, CA, United States
PA      Biocardia, Inc., South San Francisco, CA, United States (U.S.
        corporation)
PI      US 6416510          B1   20020709
AI      US 1999-418205           19991013 (9)
RLI     Continuation-in-part of Ser. No. US 1997-816850, filed on 13 Mar 1997
DT      Utility
FS      GRANTED
LN.CNT  2112
INCL    INCLM: 606/041.000
        INCLS: 607/120.000; 607/003.000
NCL     NCLM:  606/041.000
        NCLS:  607/003.000; 607/120.000
IC      [7]
        ICM: A61N001-05
EXF     607/120; 607/121; 607/122; 607/123; 607/3; 607/126; 607/127; 607/128;
        607/60-61; 607/32-33; 606/41; 606/45; 606/47; 606/48; 606/44; 606/167;
        600/508; 600/374; 604/22; 604/264; 604/95; 604/200; 604/73; 604/181;
        604/187; 604/131; 604/141; 604/143; 604/148; 604/280

L22  ANSWER 17 OF 21  USPATFULL on STN
```

```
AN      2002:158065  USPATFULL
TI      Delivery or therapeutic capable agents
IN      Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
        Yan, John, Los Gatos, CA, UNITED STATES
PA      AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S. corporation)
PI      US 2002082679      A1   20020627
AI      US 2001-2595       A1   20011101 (10)
PRAI    US 2000-258024P      20001222 (60)
        US 2001-308381P      20010726 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3153
INCL    INCLM: 623/001.150
        INCLS: 623/001.420; 424/426.000
NCL     NCLM:  623/001.150
        NCLS:  623/001.420; 424/426.000
IC      [7]
        ICM: A61F002-06
        ICS: A61F002-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 18 OF 21  USPATFULL on STN
AN      2002:92631  USPATFULL
TI      Cobalamin compounds useful as cardiovascular agents and as imaging
        agents
IN      Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
PI      US 2002049155      A1   20020425
AI      US 2001-873142     A1   20010531 (9)
PRAI    US 2000-208140P      20000531 (60)
        US 2001-267782P      20010209 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4521
INCL    INCLM: 514/007.000
NCL     NCLM:  514/007.000
IC      [7]
        ICM: A61K038-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 19 OF 21  USPATFULL on STN
AN      2002:78737  USPATFULL
TI      Cobalamin compounds useful as antibiotic agents and as imaging agents
IN      Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES
        Collins, Douglas A., Rochester, MN, UNITED STATES
PI      US 2002042394      A1   20020411
AI      US 2001-873164     A1   20010531 (9)
PRAI    US 2000-208148P      20000531 (60)
        US 2001-267543P      20010209 (60)
DT      Utility
FS      APPLICATION
LN.CNT 4896
INCL    INCLM: 514/053.000
        INCLS: 514/185.000; 540/145.000; 536/026.440
NCL     NCLM:  514/053.000
        NCLS:  514/185.000; 540/145.000; 536/026.440
IC      [7]
        ICM: A61K031-714
        ICS: A61K031-555; C07H023-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 20 OF 21  USPATFULL on STN
AN      2002:48052  USPATFULL
TI      Protein matrix materials, devices and methods of making and using
        thereof
```

```
IN      Masters, David B., Hastings, MN, UNITED STATES
PI      US 2002028243      A1   20020307
AI      US 2001-796170     A1   20010228 (9)
RLI     Continuation-in-part of Ser. No. US 1998-160421, filed on 25 Sep 1998,
        ABANDONED
PRAI    US 2000-185420P     20000228 (60)
        US 2000-222762P     20000803 (60)
DT      Utility
FS      APPLICATION
LN.CNT 3903
INCL    INCLM: 424/484.000
NCL     NCLM:  424/484.000
IC      [7]
        ICM: A61K009-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 21 OF 21  USPATFULL on STN
AN      2002:19086  USPATFULL
TI      Drug delivery devices comprising
        biodegradable protein for the controlled release of
        pharmacologically active agents and method of making the drug
        delivery devices
IN      Masters, David B., Hastings, MN, United States
PA      Gel-Del Technologies, Inc., Saint Paul, MN, United States (U.S.
        corporation)
PI      US 6342250         B1   20020129
AI      US 1998-160421          19980925 (9)
PRAI    US 1997-60048P         19970925 (60)
DT      Utility
FS      GRANTED
LN.CNT 1740
INCL    INCLM: 424/484.000
        INCLS: 424/468.000; 424/443.000
NCL     NCLM:  424/484.000
        NCLS:  424/443.000; 424/468.000
IC      [7]
        ICM: A61K009-10
        ICS: A61K009-22; A61K009-70; A61K047-42
EXF     424/486; 424/484; 424/464-465; 424/468; 424/489; 424/400; 424/443
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d L22 6 9 15 21 ibib abs

L22  ANSWER 6 OF 21  USPATFULL on STN
ACCESSION NUMBER:        2004:30716  USPATFULL
TITLE:                   Polymer-based, sustained release drug
                         delivery system
INVENTOR(S):             Ashton, Paul, Boston, MA, UNITED STATES
                         Chen, Jianbing, Belmont, MA, UNITED STATES
                         Guo, Hong, Belmont, MA, UNITED STATES
PATENT ASSIGNEE(S):      Control Delivery Systems, Inc., Watertown, MA, UNITED
                         STATES (U.S. corporation)

                             NUMBER        KIND     DATE
                         --------------- ------ --------
PATENT INFORMATION:      US 2004022853      A1   20040205
APPLICATION INFO.:       US 2003-449855     A1   20030530  (10)
RELATED APPLN. INFO.:    Continuation-in-part of Ser. No. US 2002-134033, filed
                         on 26 Apr 2002, PENDING Continuation-in-part of Ser.
                         No. WO 2002-US13385, filed on 26 Apr 2002, PENDING

                              NUMBER        DATE
                         ----------------- --------
```

```
PRIORITY INFORMATION:      US 2001-286343P    20010426 (60)
                           US 2001-322428P    20010917 (60)
                           US 2002-372761P    20020415 (60)
DOCUMENT TYPE:             Utility
FILE SEGMENT:              APPLICATION
LEGAL REPRESENTATIVE:      ROPES & GRAY LLP, ONE INTERNATIONAL PLACE, BOSTON, MA,
                           02110-2624
NUMBER OF CLAIMS:          58
EXEMPLARY CLAIM:           1
NUMBER OF DRAWINGS:        4 Drawing Page(s)
LINE COUNT:                1789
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB      Disclosed is a sustained release system that includes a polymer
        and a pharmaceutically active agent dispersed in the polymer.
        The agent is in granular or particulate form, and has a rate of release
        from the system that is limited primarily by the rate at which the agent
        dissolves from the granules into the polymer matrix.
        Advantageously, the polymer is permeable to the agent and is
        non-release-rate-with limiting with respect to the rate of release of
        the agent from the polymer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22  ANSWER 9 OF 21  USPATFULL on STN
ACCESSION NUMBER:          2003:121162  USPATFULL
TITLE:                     Apparatus and methods for variably controlled substance
                           delivery from implanted prostheses
INVENTOR(S):               Sirhan, Motasim, Sunnyvale, CA, UNITED STATES
                           Yan, John, Los Gatos, CA, UNITED STATES
PATENT ASSIGNEE(S):        AVANTEC VASCULAR CORPORATION, San Jose, CA (U.S.
                           corporation)

                                NUMBER        KIND    DATE
                           ---------------- ------ --------
PATENT INFORMATION:        US 2003083646      A1   20030501
APPLICATION INFO.:         US 2001-17500      A1   20011214  (10)
RELATED APPLN. INFO.:      Continuation-in-part of Ser. No. US 2001-2595, filed on
                           1 Nov 2001, PENDING
DOCUMENT TYPE:             Utility
FILE SEGMENT:              APPLICATION
LEGAL REPRESENTATIVE:      TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO
                           CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS:          112
EXEMPLARY CLAIM:           1
NUMBER OF DRAWINGS:        35 Drawing Page(s)
LINE COUNT:                2731
AB      The present invention provides improved stents and other prostheses for
        delivering substances to vascular and other luminal and intracorporeal
        enviroments. In particular, the present invention provides luminal
        prostheses which allow for a programmed and controlled substance
        delivery protocols for a variety of purposes. The prostheses comprise a
        scaffold which is implantable within a body lumen and a
        substance reservoir present over at least a portion of the scaffold.
        Usually, a rate-controlling element will be formed
        over the substance-containing reservoir to provide for a number of
        different substance release characteristics.


L22  ANSWER 15 OF 21  USPATFULL on STN
ACCESSION NUMBER:          2002:198316  USPATFULL
TITLE:                     Drug delivery devices comprising
                           biodegradable protein for the controlled
                           release of pharmacologically active agents and method
                           of making the drug delivery devices
```

INVENTOR(S): Masters, David B., Hastings, MN, UNITED STATES
PATENT ASSIGNEE(S): Gel-Del Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002106410	A1	20020808	
APPLICATION INFO.:	US 2001-14947	A1	20011211	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-160421, filed on 25 Sep 1998, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John F. Dolan, Fredrikson & Byron, P.A., 1100 International Centre, 900 Second Avenue South, Minneapolis, MN, 55408-3397
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making **drug delivery** devices for the controlled release of pharmacologically active agents and further, to **drug delivery** devices made by such method. More specifically, the present invention relates to a method of forming a film comprising one or more **biodegradable polymeric** materials, one or more pharmacologically active agents, and one or more biocompatible solvents. The film is then **partially** dried, rolled or otherwise shaped, and then compressed. In this manner, the amount of pharmacologically active agent(s) that can be incorporated into the **drug delivery** device is increased and the pharmacologically active agent(s) is/are substantially homogeneously distributed throughout the **drug delivery** device. As a result, the release characteristics of the pharmacologically active agent from the **drug delivery** device are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 21 OF 21 USPATFULL on STN
ACCESSION NUMBER: 2002:19086 USPATFULL
TITLE: **Drug delivery** devices comprising **biodegradable** protein for the controlled release of pharmacologically active agents and method of making the **drug delivery** devices
INVENTOR(S): Masters, David B., Hastings, MN, United States
PATENT ASSIGNEE(S): Gel-Del Technologies, Inc., Saint Paul, MN, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6342250	B1	20020129	
APPLICATION INFO.:	US 1998-160421		19980925	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60048P	19970925 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Webman, Edward J.
LEGAL REPRESENTATIVE: Fredrikson & Byron, PA
NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1740
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an improved method of making **drug delivery** devices for the controlled release of pharmacologically active agents and further, to **drug delivery** devices made by such method. More specifically, the present invention relates to a method of forming a film comprising one or more **biodegradable polymeric** materials, one or more pharmacologically active agents, and one or more biocompatible solvents. The film is then **partially** dried, rolled or otherwise shaped, and then compressed. In this manner, the amount of pharmacologically active agent(s) that can be incorporated into the **drug delivery** device is increased and the pharmacologically active agent(s) is/are substantially homogeneously distributed throughout the **drug delivery** device. As a result, the release characteristics of the pharmacologically active agent from the **drug delivery** device are enhanced.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.